FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280496528> ?p ?o ?g. }

• W4280496528 endingPage "628" @default.
• W4280496528 startingPage "614" @default.
• W4280496528 abstract "Mantle cell lymphoma is a rare B-cell non-Hodgkin lymphoma that is clinically and biologically heterogeneous. Risk stratification at the time of diagnosis is critical. One of the most powerful prognostic indices is the Mantle Cell Lymphoma International Prognostic Index-Combined, which integrates an estimate of proliferation (Ki67 index) with the standard Mantle Cell Lymphoma International Prognostic Index clinical factors. In addition, the presence of TP53 mutation is associated with suboptimal response to intensive chemoimmunotherapy and particularly dismal survival outcomes. Given their excellent activity in the relapsed/refractory setting, increasingly, biologically targeted therapeutics-such as covalent Bruton tyrosine kinase inhibitors, lenalidomide, and venetoclax-are being incorporated into chemotherapy-free regimens and in combination with established chemoimmunotherapy backbones for treatment-naïve mantle cell lymphoma. In addition, risk-adapted treatment programs are increasingly being studied. These programs tailor treatment according to baseline prognostic factors (e.g., presence of TP53 mutation) and may incorporate biomarkers of response such as minimal residual disease assessment. Although still investigational, these studies present an opportunity to move beyond the biology-agnostic, historical fitness-based treatment selection paradigm and toward a more personalized, tailored treatment approach in mantle cell lymphoma. After Bruton tyrosine kinase inhibitor failure, many promising standard or investigational therapies exist, including CAR T-cell therapy (including brexucabtagene autoleucel and lisocabtagene maraleucel), bispecific antibody therapy targeting CD20-CD3, zilovertamab vedotin (an antibody-drug conjugate that targets ROR1), and the noncovalent Bruton tyrosine kinase inhibitor pirtobrutinib. These new therapies show promising efficacy, even among high-risk patients, and will likely translate to improvements in survival outcomes for patients with progressive mantle cell lymphoma following treatment with a Bruton tyrosine kinase inhibitor." @default.
• W4280496528 created "2022-05-22" @default.
• W4280496528 creator A5021775267 @default.
• W4280496528 creator A5050427554 @default.
• W4280496528 creator A5053298824 @default.
• W4280496528 creator A5066521233 @default.
• W4280496528 creator A5089206024 @default.
• W4280496528 date "2022-07-01" @default.
• W4280496528 modified "2023-10-09" @default.
• W4280496528 title "New Directions for Mantle Cell Lymphoma in 2022" @default.
• W4280496528 cites W1829587101 @default.
• W4280496528 cites W1969049855 @default.
• W4280496528 cites W2001178238 @default.
• W4280496528 cites W2030263904 @default.
• W4280496528 cites W2049159227 @default.
• W4280496528 cites W2078761761 @default.
• W4280496528 cites W2085346499 @default.
• W4280496528 cites W2112509952 @default.
• W4280496528 cites W2124235514 @default.
• W4280496528 cites W2125684345 @default.
• W4280496528 cites W2130669641 @default.
• W4280496528 cites W2169209759 @default.
• W4280496528 cites W2184668473 @default.
• W4280496528 cites W2187899653 @default.
• W4280496528 cites W2190884983 @default.
• W4280496528 cites W2289178667 @default.
• W4280496528 cites W2430862255 @default.
• W4280496528 cites W2460527563 @default.
• W4280496528 cites W2470400696 @default.
• W4280496528 cites W2577788459 @default.
• W4280496528 cites W2589238872 @default.
• W4280496528 cites W2748428998 @default.
• W4280496528 cites W2749289906 @default.
• W4280496528 cites W2760635695 @default.
• W4280496528 cites W2766065657 @default.
• W4280496528 cites W2773054919 @default.
• W4280496528 cites W2774522106 @default.
• W4280496528 cites W2791154088 @default.
• W4280496528 cites W2795301499 @default.
• W4280496528 cites W2802559042 @default.
• W4280496528 cites W2888862072 @default.
• W4280496528 cites W2889531115 @default.
• W4280496528 cites W2890354015 @default.
• W4280496528 cites W2891539827 @default.
• W4280496528 cites W2892160172 @default.
• W4280496528 cites W2896619830 @default.
• W4280496528 cites W2900100632 @default.
• W4280496528 cites W2900472144 @default.
• W4280496528 cites W2900733038 @default.
• W4280496528 cites W2910871809 @default.
• W4280496528 cites W2917721259 @default.
• W4280496528 cites W2933124649 @default.
• W4280496528 cites W2985252139 @default.
• W4280496528 cites W2985675201 @default.
• W4280496528 cites W3003221180 @default.
• W4280496528 cites W3014583893 @default.
• W4280496528 cites W3014792348 @default.
• W4280496528 cites W3029266545 @default.
• W4280496528 cites W3036344565 @default.
• W4280496528 cites W3036787109 @default.
• W4280496528 cites W3049430822 @default.
• W4280496528 cites W3087400259 @default.
• W4280496528 cites W3088335083 @default.
• W4280496528 cites W3095555012 @default.
• W4280496528 cites W3095832065 @default.
• W4280496528 cites W3096166445 @default.
• W4280496528 cites W3096548119 @default.
• W4280496528 cites W3105196097 @default.
• W4280496528 cites W3130396248 @default.
• W4280496528 cites W3134524629 @default.
• W4280496528 cites W3137447968 @default.
• W4280496528 cites W3158081457 @default.
• W4280496528 cites W3169078835 @default.
• W4280496528 cites W3171882656 @default.
• W4280496528 cites W3172314389 @default.
• W4280496528 cites W3172497218 @default.
• W4280496528 cites W3176433809 @default.
• W4280496528 cites W3201468520 @default.
• W4280496528 cites W3202752956 @default.
• W4280496528 cites W3202904400 @default.
• W4280496528 cites W3209915357 @default.
• W4280496528 cites W3210991186 @default.
• W4280496528 cites W3211809601 @default.
• W4280496528 cites W3213114599 @default.
• W4280496528 cites W3213252454 @default.
• W4280496528 cites W3214362881 @default.
• W4280496528 cites W3214636619 @default.
• W4280496528 cites W3216583599 @default.
• W4280496528 cites W3217562101 @default.
• W4280496528 cites W3217796278 @default.
• W4280496528 cites W4200344367 @default.
• W4280496528 cites W4200440187 @default.
• W4280496528 cites W4200488914 @default.
• W4280496528 cites W4200570830 @default.
• W4280496528 cites W4206934925 @default.
• W4280496528 cites W4225471076 @default.
• W4280496528 doi "https://doi.org/10.1200/edbk_349509" @default.
• W4280496528 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35561299" @default.

• next